Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-09-16Clinical Trial Update: Comparison of the Efficacy and Mechanisms for MBCT and CT for Multiple Sclerosis (MS) Chronic Pain [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating MBCT vs CT for chronic pain in Multiple Sclerosis, examining efficacy and mechanisms.
-
CLINICAL_TRIALS trial_result · 2019-09-12Clinical Trial Update: Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis [Phase 2]
Phase 2 trial update evaluating 4-aminopyridine for cognitive performance and motor function in multiple sclerosis patients; study completed…
-
FDA approval · 2019-09-11FDA Approved: BACLOFEN (INTRATHECAL) — Original Application (MAIA Pharmaceuticals, Inc.)
FDA approved an original application for a generic intrathecal baclofen product from MAIA Pharmaceuticals, enabling marketing of intrathecal…
-
CLINICAL_TRIALS trial_result · 2019-09-10Clinical Trial Update: A Pilot Study of Lithium in Progressive Multiple Sclerosis [Phase 1, Phase 2]
Pilot study combining Phase 1/2 evaluating lithium in progressive multiple sclerosis; completed with results posted in 2019.
-
FDA approval · 2019-09-06FDA Approved: AUBAGIO — Supplemental Application (Genzyme Corporation)
The FDA approved Genzyme's supplemental application for Aubagio (teriflunomide), resulting in changes to the drug's labeling.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-08-21Clinical Trial Update: Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis [Phase 1, Phase 2]
Clinical trial update on transcranial magnetic stimulation (TMS) for multiple sclerosis covering Phase 1 and Phase 2, with unknown status.
-
FDA label_change · 2019-08-16FDA Approved: BETASERON — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for BETASERON (interferon beta-1b) filed by Bayer, resulting in labeling changes.
-
FDA label_change · 2019-08-16FDA Approved: GILENYA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for GILENYA (fingolimod hydrochloride) submitted by Novartis Pharmaceuticals Corporation; the approv…
-
CLINICAL_TRIALS trial_result · 2019-08-15Clinical Trial Update: Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects [Phase 4]
A Phase 4 trial evaluating whether prednisone can reduce side effects of pegylated interferon beta-1a in multiple sclerosis patients.
-
CLINICAL_TRIALS trial_result · 2019-08-01Clinical Trial Update: Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis [Phase 2]
Phase 2 clinical trial evaluating autologous mesenchymal bone marrow stem cells in active and progressive multiple sclerosis has completed.
-
FDA approval · 2019-07-30FDA Approved: BACLOFEN — Original Application (Sagent Pharmaceuticals)
FDA approved baclofen from Sagent Pharmaceuticals under an original ANDA, confirming the availability of generic baclofen for treating muscl…
-
EMA label_change · 2019-07-26Updated restrictions for Gilenya: multiple sclerosis medicine not to be used in pregnancy
The European Medicines Agency updates restrictions for Gilenya (fingolimod) to prohibit use during pregnancy due to potential fetal harm, re…
-
FDA label_change · 2019-07-24FDA Approved: AUBAGIO — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for AUBAGIO (teriflunomide) submitted by Genzyme Corporation.
-
CLINICAL_TRIALS trial_result · 2019-07-24Clinical Trial Update: Isokinetic Exercises in Patients With Multiple Sclerosis [NA]
Clinical trial on isokinetic exercises for patients with Multiple Sclerosis has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2019-07-24Clinical Trial Update: Integrating Caregiver Support Into MS Care [NA]
A completed clinical trial evaluating integrating caregiver support into multiple sclerosis care; results posted in 2019.
-
FDA approval · 2019-07-12FDA Approved: AVONEX — Supplemental Application (Biogen Inc.)
The FDA approved a supplemental application for AVONEX (interferon beta-1a) submitted by Biogen Inc. This action updates the regulatory stat…
-
CLINICAL_TRIALS trial_result · 2019-07-12Clinical Trial Update: Towards Personalized Dosing of Natalizumab in Multiple Sclerosis [Phase 4]
A Phase 4 clinical trial update exploring personalized dosing of natalizumab for multiple sclerosis has completed.
-
FDA approval · 2019-07-10FDA Approved: PLEGRIDY PEN — Supplemental Application (Biogen Inc.)
The FDA approved a supplemental application for PLEGRIDY PEN, the autoinjector device for peginterferon beta-1a, to be used in the treatment…
-
FDA label_change · 2019-07-10FDA Approved: TECFIDERA — Supplemental Application (Biogen Inc.)
FDA approved a supplemental application for Tecfidera (dimethyl fumarate) from Biogen. The approval updates the product labeling.
-
FDA approval · 2019-07-09FDA Approved: REBIF — Supplemental Application (EMD Serono, Inc.)
FDA approved a supplemental application for REBIF (interferon beta-1a) submitted by EMD Serono, Inc., indicating an approved update to its l…
-
CLINICAL_TRIALS trial_result · 2019-06-28Clinical Trial Update: Exploring the Use of Non-invasive Neuromodulation Combined With Exercise in People With Advanced Multiple Sclerosis (MS) [NA]
Completed clinical trial investigating non-invasive neuromodulation combined with exercise for people with advanced multiple sclerosis; resu…
-
CLINICAL_TRIALS trial_result · 2019-06-27Clinical Trial Update: Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). [Phase 3]
Phase 3 trial update assessing BG00012 effects on lymphocyte subsets and immunoglobulins in relapsing-remitting multiple sclerosis; study co…
-
CLINICAL_TRIALS trial_result · 2019-05-29Clinical Trial Update: Wearable Lower Extremity Exoskeleton to Promote Walking in Persons With Multiple Sclerosis [NA]
A completed clinical trial investigating a wearable lower-extremity exoskeleton to promote walking in persons with multiple sclerosis, with …
-
FDA approval · 2019-05-21FDA Approved: DALFAMPRIDINE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical's generic dalfampridine (Dalfampridine) for improving walking in adults with multiple sclerosis through an O…
-
CLINICAL_TRIALS trial_result · 2019-05-16Clinical Trial Update: BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies [Phase 4]
Long-term follow-up results from the BENEFIT program in multiple sclerosis have completed phase 4 assessments.